CoChat

Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study

Open access

The DOI matches its Crossref record; 60 of the 65 references it cites were found in a registry or an index; 6 of the 31 sources its claims cite were checked for support.

Abstract

Objectives: A reduced adrenal reserve-associated cortisol production relative to the enhanced needs of chronic inflammation (disproportion principle) has been observed in rheumatoid arthritis (RA). We examined the possible clinical value of diurnal cortisol measurements in active RA on treatment response prediction. Methods: Diurnal cortisol production (measured at: 08–12:00/18:00–22:00) was assessed by electrochemiluminescence immunoassay in 28 consecutive patients with moderately/highly active RA, as well as 3 and 6 months after treatment initiation or/escalation. Twenty-eight COVID-19 patients and 28 age-matched healthy individuals (HC) served as controls. Results: Saliva diurnal cortisol production in patients with RA was similar to that of HC, despite 12-fold higher serum C reactive protein (CRP) levels, and lower than COVID-19 patients (area under the curve: RA: 87.0±37.6 vs COVID-19: 146.7±14.3, p<0.001), having similarly high CRP. Moreover, a disturbed circadian cortisol rhythm at baseline was evident in 15 of 28 of patients with RA vs 4 of 28 and 20 of 28 of HC and COVID-19 patients, respectively. Treatment-induced minimal disease activity (MDA) at 6 months was achieved by 16 of 28 patients. Despite comparable demographics and clinical characteristics at baseline, non-MDA patients had lower baseline morning cortisol and higher adrenocorticotropic hormone (ACTH) levels compared with patients on MDA (cortisol: 10.9±4.0 vs 18.4±8.2 nmol/L, respectively, p=0.005 and ACTH: 4.8±3.3 vs 2.4±0.4 pmol/L, respectively, p=0.047). Baseline morning cortisol <13.9 nmol/L predicted non-MDA at 6 months (75% sensitivity, 92% specificity, p=0.006). Prospective measurements revealed that individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months. Conclusions: An impaired adrenal reserve is present in patients with RA. Further studies to confirm that assessment of diurnal cortisol production may be useful in guiding treatment decisions and/or predicting treatment response in RA are warranted. Trial registration number: NCT05671627.

Overview

CoChat Summary

TL;DR

In a 6-month real-life prospective cohort of 28 patients with active rheumatoid arthritis (RA), diurnal saliva cortisol production was comparable to healthy controls despite high inflammation and lower than in COVID-19 controls, suggesting impaired adrenal reserve. Baseline morning saliva cortisol <13.9 nmol/L predicted failure to achieve minimal disease activity (MDA) at 6 months with 75% sensitivity and 92% specificity.

Key findings

  • Patients with active RA had saliva cortisol levels and time-integrated daily cortisol production comparable to healthy controls despite 12-fold higher CRP; night cortisol was higher in RA than controls (4.0±3.5 vs 1.9±0.8 nmol/L, p=0.005). RA patients had lower time-integrated daily cortisol production than COVID-19 patients (AUC 87±38 vs 147±75, p<0.001 in Results; abstract reports RA 87.0±37.6 vs COVID-19 146.7±14.3, p<0.001).
  • A disturbed circadian cortisol rhythm was present in 15/28 RA patients vs 4/28 healthy controls and 20/28 COVID-19 patients (both p<0.01).
  • At 6 months, 16/28 patients achieved MDA. Non-MDA patients had lower baseline morning saliva cortisol (10.9±4.0 vs 18.4±8.2 nmol/L, p=0.005) and higher ACTH (4.8±3.3 vs 2.4±0.4 pmol/L, p=0.047) than MDA patients. Baseline morning saliva cortisol <13.9 nmol/L predicted non-MDA (75% sensitivity, 92% specificity, p=0.006; adjusted OR 53.7, 95% CI 3.9 to 744). Of seven patients with both morning cortisol <13.9 nmol/L and disturbed rhythm, none achieved MDA.
  • Individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months despite treatment-induced changes in disease activity and stress.

Methods

  • Single-centre, 6-month prospective cohort: 30 consecutive patients with moderately/highly active RA (DAS28 >3.2) enrolled; 28 completed (24 female). Thirteen were newly diagnosed and initiated DMARDs; 15 required DMARD escalation. Controls were 28 age-matched healthy individuals and 28 age-matched COVID-19 patients from a previously published cohort.
  • Saliva cortisol was measured at 08:00, 12:00, 18:00 and 22:00 by electrochemiluminescence immunoassay; plasma ACTH and serum CRP were measured at 08:00. Time-integrated daily cortisol production was calculated as AUC using the trapezoidal method. Assessments occurred at baseline, 3 and 6 months; MDA was defined as DAS28–ESR ≤2.85.
  • Analyses included t-tests/Mann-Whitney U tests, Fisher’s exact test, ANOVA/Kruskal-Wallis with post hoc tests, repeated-measures tests, linear and logistic regression, and ROC curve analysis. No power calculation was performed in advance.

Limitations

  • Stated by the authors: small sample size; inclusion of both early and established RA; explanatory analysis without power calculation; no unified treatment protocol and not all EULAR/ACR core set measures were recorded; stress and depression were not systematically assessed in control groups; no control group of patients with inactive RA at baseline.
  • Evident from the text: single-centre real-life design with heterogeneous treatments; healthy and COVID-19 controls had limited sampling (baseline only for healthy controls and one time point for COVID-19 controls); small subgroup sizes limit precision of predictive estimates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/rmdopen-2023-003575

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Diurnal saliva cortisol levels (A), time-integrated daily saliva cortisol production (B) and serum CRP levels (C) at baseline in patients with RA, COVID-19 patients and healthy controls (HC). Saliva cortisol levels were measured at 08:00, 12:00, 18:00 and 22:00, and the time-integrated daily saliva cortisol production was calculated as the total area under the curve (AUC). Lines in (A) represent mean±SEM, and in (B) and (C) represent mean±SD. P values are derived from one-way ANOVA followed by Bonferroni multiple comparisons test or the non-parametric Kruskal-Wallis followed by Dunn’s multiple comparisons test for measurements that did not follow a normal distribution (saliva cortisol measurements did not follow a normal distribution). *P<0.05 compared with controls; #p<0.05 compared with patients with RA. ANOVA, analysis of variance; CRP, C reactive protein; RA, rheumatoid arthritis.
Figure 1 Diurnal saliva cortisol levels (A), time-integrated daily saliva cortisol production (B) and serum CRP levels (C) at baseline in patients with RA, COVID-19 patients and healthy controls (HC). Saliva cortisol levels were measured at 08:00, 12:00, 18:00 and 22:00, and the time-integrated daily saliva cortisol production was calculated as the total area under the curve (AUC). Lines in (A) represent mean±SEM, and in (B) and (C) represent mean±SD. P values are derived from one-way ANOVA followed by Bonferroni multiple comparisons test or the non-parametric Kruskal-Wallis followed by Dunn’s multiple comparisons test for measurements that did not follow a normal distribution (saliva cortisol measurements did not follow a normal distribution). *P<0.05 compared with controls; #p<0.05 compared with patients with RA. ANOVA, analysis of variance; CRP, C reactive protein; RA, rheumatoid arthritis.CC BY-NC · PubMed Central
Figure 2 Receiver operating characteristic curve for baseline morning saliva cortisol levels predicting no minimal disease activity (DAS >2.85) at 6 months in patients with RA. AUC: 0.807, 95% CI: 0.634 to 0.981, p=0.006. AUC, area under the curve; DAS, Disease Activity Score; RA, rheumatoid arthritis.
Figure 2 Receiver operating characteristic curve for baseline morning saliva cortisol levels predicting no minimal disease activity (DAS >2.85) at 6 months in patients with RA. AUC: 0.807, 95% CI: 0.634 to 0.981, p=0.006. AUC, area under the curve; DAS, Disease Activity Score; RA, rheumatoid arthritis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 14 Not checked · 55 Own results and interpretations

39 more claims

Create a free account to see all 72 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. 10.1136/ard-2022-223356 · doi:10.1136/ard-2022-223356 · Paper page

Cited by

See all 13

Metadata

Authors
Yavropoulou, M. P., Filippa, M. G., Vlachogiannis, N. I., Fragoulis, G. E., Laskari, K., Mantzou, A., Panopoulos, S., Fanouriakis, A., Bournia, V.-K., Evangelatos, G., Papapanagiotou, A., Tektonidou, M. G., Chrousos, G. P., & Sfikakis, P. P.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece
Corresponding author
Sfikakis, Petros P
Venue
RMD Open
Publisher
BMJ
Published
2024-01
Volume
10
Issue
1
Pages
e003575
ISSN
2056-5933 (ISSN-L)
OpenAlex
W4390956188
Cited by
13
References
65
Citations by year
2026: 4 · 2025: 5 · 2024: 4
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • RMD Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
rheumatoid arthritis, diurnal cortisol rhythm, treatment response prediction, minimal disease activity, ACTH, adrenal reserve, C-reactive protein, COVID-19 pandemic, salivary cortisol, disease activity monitoring
MeSH terms
COVID-19, Adrenocorticotropic Hormone, Arthritis, Rheumatoid, Humans, Hydrocortisone, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. https://app.cochat.ai/papers/10.1136/rmdopen-2023-003575
The paper
Yavropoulou, M. P., Filippa, M. G., Vlachogiannis, N. I., Fragoulis, G. E., Laskari, K., Mantzou, A., Panopoulos, S., Fanouriakis, A., Bournia, V.-K., Evangelatos, G., Papapanagiotou, A., Tektonidou, M. G., Chrousos, G. P., & Sfikakis, P. P. (2024). Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD Open. https://doi.org/10.1136/rmdopen-2023-003575

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.